Anti-angiogenesis target therapy for advanced osteosarcoma
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Osteosarcomas (OS), especially those with metastatic or unresectable disease, have limited treatment options. The greatest advancement in treatments occurred in the 1980s when multi-agent chemotherapy, including doxorubicin, cisplatin, high-dose methotrexate, and, in some regimens, ifosfamide, was demonstrated to improve overall survival compared with surgery alone. However, standard chemotherapeutic options have been limited by poor response rates in patients with relapsed or advanced cases. It has been reported that VEGFR expression correlates with the outcome of patients with osteosarcoma and circulating VEGF level has been associated with the development of lung metastasis. At present, it seems to us that progress has not been made since Grignani reported a phase II cohort trial of sorafenib and sorafenib combined with everolimus for advanced osteosarcoma, which, in a sense, have become a milestone as a second-line therapy for osteosarcoma. Although the recognization of muramyltripepetide phosphatidyl-ethanolamine has made some progress based on its combination with standard chemotherapy, its effect on refractory cases is controversial. Personalized comprehensive molecular profiling of high-risk osteosarcoma up to now has not changed the therapeutic prospect of advanced osteosarcoma significantly. Thus, how far have we moved forward and what therapeutic strategy should we prefer for anti-angiogenesis therapy? This review provides an overview of the most updated anti-angiogenesis therapy in OS and discusses some clinical options in order to maintain or even improve progression-free survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 3×
“Sorafenib TKIs veGfR-2 (90), Raf-1 (6), B-Raf (22), (15,16,35,70,71,86)”
BackgroundPaclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761 · cited 1×
“However, synergism of anti-angiogenetics and chemotherapeutics has been observed in patients with colon cancers (105), non-small cell lung cancers (106), and breast cancers (107,108).”
BackgroundEndostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · cited 2×
“PeDf A secreted glycoprotein that non-specific (47-52,74)”
BackgroundBlume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691 · cited 1×
“With innovation from the veGf-A aptamer (55) to VEGF trap (56), more focus has been given to the VEGFR tyrosine kinase inhibitors (TKIs) (7,16).”
BackgroundCasanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Kempf-Bielack, B., Bielack, S. S., Jürgens, H., Branscheid, D., Berdel, W. E., Exner, G. U., Göbel, U., Helmke, K., Jundt, G., Kabisch, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.063 · Cited by 643 · cited 1×
“In some cases, through aggressive surgical resection of all gross disease, patients can still acquire long-term survival (69,70).”
BackgroundGrignani, G., Palmerini, E., Dileo, P., Asaftei, S. D., D’Ambrosio, L., Pignochino, Y., Mercuri, M., Picci, P., Fagioli, F., Casali, P. G., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr151 · Cited by 359
Demetri, G. D., Chawla, S. P., Ray-Coquard, I., Le Cesne, A., Staddon, A. P., Milhem, M. M., Penel, N., Riedel, R. F., Bui-Nguyen, B., Cranmer, L. D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.5766 · Cited by 245
Ebb, D., Meyers, P., Grier, H., Bernstein, M., Gorlick, R., Lipshultz, S. E., Krailo, M., Devidas, M., Barkauskas, D. A., Siegal, G. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4546 · Cited by 243
Allen, E., Miéville, P., Warren, C. M., Saghafinia, S., Li, L., Peng, M.-W., & Hanahan, D. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.029 · Cited by 221 · cited 1×
“This signal pathway was not originally activated in most sarcoma patients (65), but after using antiangiogenesis TKIs for a while, many sarcomas show secondary activated pathway, which makes this target as a supplement to TKIs for long-term use (66).”
BackgroundLagmay, J. P., Krailo, M. D., Dang, H., Kim, A., Hawkins, D. S., Beaty, O., Widemann, B. C., Zwerdling, T., Bomgaars, L., Langevin, A.-M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.5381 · Cited by 190 · cited 4×
“From the review of van Maldegem et al (2) and Lagmay et al (4), we concluded that in the past two decades, published phase I/II clinical trials on chemotherapy for osteosarcoma failed to make significant progress in refractory cases.”
BackgroundInfluentialSégaliny, A. I., Tellez-Gabriel, M., Heymann, M.-F., & Heymann, D. (2015) · Journal of Bone Oncology · doi:10.1016/j.jbo.2015.01.001 · Cited by 164
Cited by
The Osteosarcoma Microenvironment: A Complex but Targetable Ecosystem
Corre, I., Verrecchia, F., Crenn, V., Redini, F., & Trichet, V. (2020) · Cells · doi:10.3390/cells9040976 · Cited by 474
Xie, L., Xu, J., Sun, X., Tang, X., Yan, T., Yang, R., & Guo, W. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0542 · Cited by 128
Self-citationGaspar, N., Venkatramani, R., Hecker-Nolting, S., Melcon, S. G., Locatelli, F., Bautista, F., Longhi, A., Lervat, C., Entz-Werle, N., Casanova, M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00387-9 · Cited by 89
Gaspar, N., Campbell-Hewson, Q., Gallego Melcon, S., Locatelli, F., Venkatramani, R., Hecker-Nolting, S., Gambart, M., Bautista, F., Thebaud, E., Aerts, I., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100250 · Cited by 59
Li, X., Wang, L., Wang, L., Yu, J., Lu, G., Zhao, W., Miao, C., Zou, C., & Wu, J. (2020) · Biomaterials Science · doi:10.1039/d0bm01296c · Cited by 28
Metadata
- Authors
- Xie, L., Ji, T., & Guo, W.
- Venue
- Oncology Reports
- Publisher
- Spandidos Publications
- Published
- 2017-02
- Volume
- 38
- Issue
- 2
- Pages
- 625-636
- ISSN
- 1021-335X (ISSN-L)
- 1791-2431
- OpenAlex
- W2666404417
- Cited by
- 119
- References
- 13
- FWCI
- 8.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.